After a year of tough headlines for advanced therapies, today’s surge is a reminder: 𝐆𝐓 𝐢𝐬 𝐚𝐥𝐢𝐯𝐞 𝐚𝐧𝐝 𝐰𝐞𝐥𝐥. Science, patients, and capital markets are finding alignment again. Well…

LinkedIn respects your privacy

LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.

Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.

Tay Salimullah’s Post

Tay Salimullah

Biotech Breakthroughs to Boardroom

After a year of tough headlines for advanced therapies, today’s surge is a reminder: 𝐆𝐓 𝐢𝐬 𝐚𝐥𝐢𝐯𝐞 𝐚𝐧𝐝 𝐰𝐞𝐥𝐥. Science, patients, and capital markets are finding alignment again. Well done uniQure team!

3 Comments

Benjamin McLeod

Founder @ Convey Bio | Co-Host of Bio2Bedside | Curating advanced therapeutic science | Biotech content strategist

Finally. So awesome to see. Biotechnology is a rollercoaster - you only get hurt if you jump off early!

1 Reaction

Jose Manuel Garnica

Experienced, independent thought leader in the Value & Access and Health Economics fields, with broad and deep global exposure and proven leadership capabilities in cell therapy, oncology, neuroscience and vaccines.

Fantastic! We need to continue to work on #patientaccess. Access is the word!

LinkedIn respects your privacy

Tay Salimullah’s Post

More from this author

Which unreasonable system are you part of?

Are we ready?

When purpose transcends timezones...

Explore content categories